Upfront Briefing
Vertex put a Phase 3 kidney win on the board and said it will seek FDA approval by month-end — exactly the kind of de-risking that starts to make “beyond CF” models feel less theoretical.
Meanwhile, financing windows stayed wide open: Dianthus priced an upsized $625M follow-on, Xenon landed an upsized $650M offering, and BioXcel took the registered-direct route for a much smaller $8.0M survival raise.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,781.48 |
(0.2%) |
(0.9%) |
| Nasdaq 100 |
24,956.5 |
0.0% |
(1.0%) |
| Russell 2000 |
2,548.08 |
(0.2%) |
+2.7% |
| Healthcare (XLV) |
153.15 |
(0.7%) |
(1.5%) |
| Biotech (XBI) |
127.4 |
+0.2% |
+4.9% |
| Nasdaq Biotech (NBI) |
5,944.5 |
+0.7% |
+4.2% |
| Clinical Trials (BBC) |
43.36 |
+1.7% |
+15.2% |
|
-
Biotech outperformed a choppy macro tape: NBI rose +0.7% and XBI +0.2% even as the S&P 500 slipped (0.2%), with sector strength driven more by company-specific flow than broad risk appetite.
-
The relative bid made sense: Vertex’s Phase 3 IgAN win helped de-risk a meaningful non-CF growth leg, while large-cap biotech financing windows remained open as Dianthus and Xenon both priced heavily upsized offerings.
-
BBC again led higher-beta biotech exposure, suggesting investors were still willing to own clinical-risk into catalysts even as renewed oil / geopolitical volatility kept the broader market mixed.
-
Market data: U.S. cash close Tue 10-Mar-2026 (YTD % vs Fri 02-Jan-2026 close).
The Big 3
|
1
|
Dianthus prices upsized $625M underwritten public offering
|
- Dianthus priced 7.31M shares at $81 (plus 0.40M pre-funded warrants) for ~$625M gross, with close expected Mar. 12 and a 30-day greenshoe.
-
Why it matters:
A $625M upsized raise, priced after a clear Phase 3 GO decision, materially reduces execution risk across Dianthus’ late-stage autoimmune build-out. More importantly, the market absorbing that size near highs says investors are still willing to fund differentiated Phase 3 immunology stories at scale.
- Source: PR
|
|
2
|
Vertex reports Phase 3 win for kidney drug, plans FDA filing
|
- Vertex said povetacicept met the Phase 3 RAINIER interim endpoint in IgA nephropathy, cutting proteinuria 52% at Week 36; an FDA filing is targeted by end-March.
-
Why it matters:
This is not just another positive readout. A strong Phase 3 interim in IgAN sharpens the commercial case for povetacicept, validates Vertex’s Alpine acquisition logic, and gives investors a more concrete non-CF growth driver heading into a likely near-term filing.
-
Source:
Endpoints
|
| 3 | BioXcel announces about $8.0M registered direct offering |
-
BioXcel agreed to a registered direct for 4.50M shares plus 4.50M 5-year warrants at $1.739 (warrants $1.614 strike), for ~$8.0M gross proceeds.
-
Why it matters:
This is classic survival financing: small absolute dollars, but expensive paper and warrant overhang. For investors, the question is not whether runway extends — it does — but whether the incremental capital is enough to bridge to value-inflecting catalysts without forcing another dilutive reset.
-
Source:
PR
|
Everything Else that broke
-
Artiva reports FY2025 results; flags RA data timing. — PR
-
vTv reports Q4 and FY2025 results, provides corporate update. — PR
-
Skye Bioscience reports Q4 and FY2025 results, plus business update. — PR
-
SIGA reports FY2025 results and provides business update. — PR
-
Shoulder Innovations reports Q4 and FY2025 financial results. — PR
-
BioNTech founders Uğur Şahin and Özlem Türeci plan to step down and launch a new mRNA venture. — Reuters
-
Sandoz is creating a standalone biosimilars unit as it positions for the next patent-loss cycle. — Fierce Pharma
-
Lundbeck’s CEO weighed in on European drug pricing and the region’s biotech competitiveness. — Endpoints
-
Edgewise posted long-term sevasemten data in Becker muscular dystrophy, extending durability discussion around its muscle program. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Celularity grants an exclusive biomaterials license/commercialization partnership; up to $35M upfront+milestones plus royalties, while retaining manufacturing. — PR
-
Rapport signs Tenacia deal for RAP-219 in Greater China: $20M upfront and up to $328M total potential consideration, adding non-dilutive support behind the Phase 3 oral seizure program. — BioWorld
VC / Private Financings
-
Breakout Ventures raises $114M Fund III to back early-stage, AI-native biotechs. — BioSpace
-
Longeveron announces up to $30M private placement: $15M upfront, led by Coastlands Capital and joined by Janus Henderson Investors, Logos Capital and Kalehua Capital; a milestone-linked second tranche can add another $15M. — PR
-
Bioretec plans a rights issue of at least €5M and up to €15M, with up to 1.5B new shares. — PR
IPOs / Follow-Ons
-
Dianthus prices upsized $625M offering (7.31M shares at $81 + 0.40M pre-funded warrants). — PR
-
Xenon prices upsized $650M public offering (10.53M shares + 0.88M pre-funded warrants at $57.00); J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets and William Blair lead. — PR
-
BioXcel announces about $8.0M registered direct offering. — PR
|
